Author:
Liu Yaxuan,Chen Lei,Ji Yibing
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference18 articles.
1. European Marketing Authorization, Valdoxan (Agomelatine): Summary of Product Characteristics, 2009.
2. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study;Loo;Int. Clin. Psychopharmacol.,2002
3. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double blind study;Hale;Int. Clin. Psychopharmacol.,2010
4. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline;Kasper;J. Clin. Psychiatry,2010
5. Improvement in subjective sleep in major depressive disorder with a nove antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine;Lemoine;J. Clin. Psychiatry,2007
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献